EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation

Wenfang Yao, Duiping Feng, Weihua Bian, Longyan Yang, Yang Li, Zhiyu Yang, Ying Xiong, Junfang Zheng, Renyou Zhai, Junqi HeAmino 2012 · DOI

Abstract

Ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50) suppresses breast cancer cell proliferation, potentially through its regulatory effect on epidermal growth factor receptor (EGFR) signaling, although the mechanism by which this occurs remains unknown. Thus in our studies, we aimed to determine the effect of EBP50 expression on EGF-induced cell proliferation and activation of EGFR signaling in the breast cancer cell lines, MDA-MB-231 and MCF-7. In MDA-MB-231 cells, which express low levels of EBP50, EBP50 overexpression inhibited EGF-induced cell proliferation, ERK1/2 and AKT phosphorylation. In MCF-7 cells, which express high levels of EBP50, EBP50 knockdown promoted EGF-induced cell proliferation, ERK1/2 and AKT phosphorylation. Knockdown of EBP50 in EBP50-overexpressed MDA-MB-231 cells abrogated the inhibitory effect of EBP50 on EGF-stimulated ERK1/2 phosphorylation and restoration of EBP50 expression in EBP50-knockdown MCF-7 cells rescued the inhibition of EBP50 on EGF-stimulated ERK1/2 phosphorylation, further confirming that the activation of EGF-induced downstream molecules could be specifically inhibited by EBP50 expression. Since EGFR signaling was triggered by EGF ligands via EGFR phosphorylation, we further detected the phosphorylation status of EGFR in the presence or absence of EBP50 expression. Overexpression of EBP50 in MDA-MB-231 cells inhibited EGF-stimulated EGFR phosphorylation, whereas knockdown of EBP50 in MCF-7 cells enhanced EGF-stimulated EGFR phosphorylation. Meanwhile, total expression levels of EGFR were unaffected during EGF stimulation. Taken together, our data shows that EBP50 can suppress EGF-induced proliferation of breast cancer cells by inhibiting EGFR phosphorylation and blocking EGFR downstream signaling in breast cancer cells. These results provide further insight into the molecular mechanism by which EBP50 regulates the development and progression of breast cancer.

Introduction

The overactivation of the Epidermal Growth Factor Receptor (EGFR) is a hallmark of many cancers, including breast cancer. When EGF binds to this receptor, it triggers a cascade of phosphorylation events that signal the cell to divide and survive. While researchers knew that the protein EBP50 could suppress breast cancer growth, the exact molecular "brake" it applied to the EGFR pathway remained a mystery. This study investigates whether EBP50 directly interferes with the initial steps of EGFR activation, preventing the growth signal from propagating through the cell's internal machinery.

Methods

The researchers utilized two distinct human breast cancer cell lines to model different EBP50 environments: MDA-MB-231 (naturally low EBP50) and MCF-7 (naturally high EBP50).

Genetic manipulation was used to alter EBP50 levels: stable transfection was used to overexpress EBP50 in MDA-MB-231 cells, while RNA interference (siRNA/shRNA) was used to knock down EBP50 in MCF-7 cells. The success of these manipulations was verified via Western blotting.

Western blot analysis confirming EBP50 overexpression in MDA-MB-231 cells (A) and knockdown in MCF-7 cells (B).

Proliferation was measured using CCK-8 and BrdU incorporation assays. Crucially, Western blotting was also used to visualize the phosphorylation status (activation) of EGFR and its downstream targets, ERK1/2 and AKT, following EGF stimulation.

Results

EBP50 Acts as a Potent Growth Suppressor

The study demonstrated that EBP50 levels directly correlate with the inhibition of cell growth. In MDA-MB-231 cells, overexpressing EBP50 reduced EGF-induced cell proliferation by approximately 26% by day 4. Conversely, knocking down EBP50 in MCF-7 cells significantly enhanced proliferation, showing up to a 40% increase compared to controls.

Cell proliferation assays showing that EBP50 overexpression inhibits growth in MDA-MB-231 (C) while EBP50 knockdown promotes growth in MCF-7 (D).

Inhibition of the EGFR "Master Switch"

The most significant insight is that EBP50 inhibits the initial phosphorylation of the EGFR receptor itself. In control cells, EGF stimulation triggered a 9.3-fold increase in EGFR phosphorylation. In the presence of overexpressed EBP50, this activation was held to less than 2.5-fold. Importantly, the total amount of EGFR protein remained unchanged; EBP50 only affected its activation state.

By blocking EGFR at the source, EBP50 simultaneously dampens downstream signaling. For example, the 12.3-fold increase in ERK1/2 phosphorylation seen in control cells was slashed to only a 5.3-fold increase in EBP50-overexpressing cells. Rescue experiments, where EBP50 expression was restored in knockdown cells, successfully returned the growth-inhibitory phenotype, confirming EBP50 as the specific driver of these effects.

Discussion and Conclusion

The authors propose a "steric hindrance" model where EBP50 binds to the carboxyl-terminal regulatory domain of EGFR. Because this domain is adjacent to the receptor's autophosphorylation sites, EBP50 may physically mask them, preventing kinases from reaching and activating the receptor. This dual-pathway suppression of both MAPK/ERK (division) and PI3K/AKT (survival) makes EBP50 a critical regulator of tumor progression.

While these results provide a clear molecular mechanism in vitro, future work is required to map the exact structural interface and validate these findings in animal models. Clinically, EBP50 levels could serve as a valuable biomarker for prognosis or as a predictor of response to EGFR-targeted therapies in breast cancer patients.

Summary updated

Abstract

Ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50) suppresses breast cancer cell proliferation, potentially through its regulatory effect on epidermal growth factor receptor (EGFR) signaling, although the mechanism by which this occurs remains unknown. Thus in our studies, we aimed to determine the effect of EBP50 expression on EGF-induced cell proliferation and activation of EGFR signaling in the breast cancer cell lines, MDA-MB-231 and MCF-7. In MDA-MB-231 cells, which express low levels of EBP50, EBP50 overexpression inhibited EGF-induced cell proliferation, ERK1/2 and AKT phosphorylation. In MCF-7 cells, which express high levels of EBP50, EBP50 knockdown promoted EGF-induced cell proliferation, ERK1/2 and AKT phosphorylation. Knockdown of EBP50 in EBP50-overexpressed MDA-MB-231 cells abrogated the inhibitory effect of EBP50 on EGF-stimulated ERK1/2 phosphorylation and restoration of EBP50 expression in EBP50-knockdown MCF-7 cells rescued the inhibition of EBP50 on EGF-stimulated ERK1/2 phosphorylation, further confirming that the activation of EGF-induced downstream molecules could be specifically inhibited by EBP50 expression. Since EGFR signaling was triggered by EGF ligands via EGFR phosphorylation, we further detected the phosphorylation status of EGFR in the presence or absence of EBP50 expression. Overexpression of EBP50 in MDA-MB-231 cells inhibited EGF-stimulated EGFR phosphorylation, whereas knockdown of EBP50 in MCF-7 cells enhanced EGF-stimulated EGFR phosphorylation. Meanwhile, total expression levels of EGFR were unaffected during EGF stimulation. Taken together, our data shows that EBP50 can suppress EGF-induced proliferation of breast cancer cells by inhibiting EGFR phosphorylation and blocking EGFR downstream signaling in breast cancer cells. These results provide further insight into the molecular mechanism by which EBP50 regulates the development and progression of breast cancer.
BibTeX
@inproceedings{yao2012ebp,
  author = {Wenfang Yao and Duiping Feng and Weihua Bian and Longyan Yang and Yang Li and Zhiyu Yang and Ying Xiong and Junfang Zheng and Renyou Zhai and Junqi He},
  title = {{EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation}},
  booktitle = {Amino},
  year = {2012},
  doi = {10.1007/s00726-012-1277-z},
}
Figure